For those that missed it... ➖ Combined Meeting ASSH-AHSS ➖...

For those that missed it...

➖ Combined Meeting ASSH-AHSS ➖

Exploring new technologies in nerve repair was a major focus at the 2024 Innovations Across the Pacific in Hand Surgery conference. hashtag#Orthocell was thrilled to join the combined meeting of the American Society for Surgery of the Hand (ASSH) and the Australian Hand Surgery Society (AHSS) in Maui as a proud Silver Sponsor.

It was a privilege to connect with over 300 surgeons from Australia, New Zealand and the USA eager to explore the cutting-edge technologies in nerve repair surgery, and our team was especially energised by the positive feedback from the surgical community surrounding Remplir.

Our Company presented data on how Remplir is redefining nerve repair assisting surgeons to consistently return muscle function to paralysed upper limbs – and surgeons on the ground confirmed that they are looking for new and better ways to improve patient outcomes in this space.

Some of the highlights from the conference included:

▶ Orthocell hosted an Industry Forum, moderated by CEO Paul Anderson, exploring how Remplir is redefining nerve repair and regeneration. The event was very well received and concluded with lively Q&A.

▶ Orthopaedic surgeon and key opinion leader Dr Alex O’Beirne co-moderated a general session on Peripheral Nerve Injuries, where he also presented on his experiences with Remplir.

▶ Orthocell co-founder and Chief Scientific Officer, Professor Ming Hao Zheng presented a paper titled ‘Sutureless Repair of Transacted Nerves Using Photo-activated Epineural Collagen’ which was rated in the Top 10 poster presentations.

▶ Three paper presentations spotlighting Orthocell’s regenerative medicine technology sparked significant audience interest. These included Dr. David Gamble's presentation on Remplir for nerve repair and neuroma management, Dr. Alex O'Beirne's study on Remplir in upper-extremity nerve reconstruction.

▶ Dr. Jason Harvey's research on OrthoATI for severe tendonitis of the elbow was the number 3 ranked paper for the whole meeting.

Orthocell CEO and MD, Paul Anderson, said:

“This event was a strong endorsement of our progress to date – the surgical community was incredibly excited to learn more about our Remplir and OrthoATI technology. Having our key papers ranked so highly, among globally respected key opinion leaders, puts energy in our stride as we focus our efforts on growing uptake of Remplir in Australia, New Zealand and prepare for its approval and launch in the USA. This is a truly exciting time for our Company.”